Development of a new anti-cancer therapy by bio-drug delivery system with somatic stem cells
| Project/Area Number |
25430160
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Osaka Medical College |
|---|
Principal Investigator |
II MASAAKI 大阪医科大学, 実験動物部門, 講師 (10442922)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TABATA YASUHIKO 京都大学, 再生組織構築研究部門 生体材料学分野, 教授 (50211371)
|
|---|
| Research Collaborator |
AOKI MASAHIKO
|
|---|
| Project Period (FY) |
2013-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | がん治療 / 脂肪幹細胞 / DDS / 抗がん剤 / 膵癌 / 癌治療 / ドラッグデリバリー / 体性幹細胞 |
|---|
| Outline of Final Research Achievements |
We made a biodegradable anti-cancer drug (Pirarubicin: Pir) conjugated PLGA nanoparticle, and loaded them into human adipose-derived mesenchymal stem cells generating a cell-complex (PirNP-hAdSC). The in vitro experiment in which human pancreatic cancer cells (KP1N) and PirNP-hAdSCs were co-cultured exhibited significant inhibition of proliferation and migration and promotion of apoptosis in KP1N cells. We will evaluate tumor growth in KP1N bearing immunodeficient mice after intravenous administration of 1) PBS, 2) PirNP alone, 3) hAdSCs alone, and 4) PirNP-hAdSCs upto 4 weeks after KP1N transplantation with one week interval.
|
Report
(5 results)
Research Products
(1 results)
